Fig. 3From: Real-world treatment patterns, healthcare resource use and clinical outcomes of patients receiving second line therapy for advanced or metastatic gastric cancerOverall survival from initiation of 2 L treatment. a OS with monotherapy, doublet therapy, triplet therapy, and overall; b OS with taxane monotherapy, irinotecan monotherapy, fluoropyrimidine + irinotecan, fluoropyrimidine + platinum, and overallBack to article page